
EDSA Stock Forecast & Price Target
EDSA Analyst Ratings
Bulls say
Edesa Biotech Inc's EB01 demonstrated significant improvements in skin health for allergic contact dermatitis (ACD) patients in a Phase 2b trial, indicating the potential for a safer alternative to traditional corticosteroids and calcineurin inhibitors. The ongoing exploration of its drug candidates, including EB05 and EB07, presents opportunities for expansion into new indications and markets, which could enhance projected sales and revenue growth. With a successful track record in clinical trials and a robust pipeline, Edesa Biotech is well-positioned for potential financial gains in the biotechnology sector focused on treating immune-related diseases.
Bears say
Edesa Biotech is projected to experience continued negative cash flows from operating activities through FY2025 and FY2026, indicating a prolonged financial strain. Additionally, the company has faced challenges in its clinical trials, including a higher-than-expected dropout rate that could hinder the progress of its product pipeline. With operating cash flows reported as negative in FY2024, financial stability appears to be a significant concern for the company's future growth prospects.
This aggregate rating is based on analysts' research of Edesa Biotech Inc and is not a guaranteed prediction by Public.com or investment advice.
EDSA Analyst Forecast & Price Prediction
Start investing in EDSA
Order type
Buy in
Order amount
Est. shares
0 shares